Now just emerging from a year of legal and financial blows and bad publicity, SFBC has decided to change its name to PharmaNet Development Group, pending shareholder approval later this month. The company’s late stage division will continue to be called PharmaNet, and its early stage divisions will operate under the names Anapharm and Taylor Technology.

SFBC’s second quarter shows how this difficult year has affected the company’s balance sheet. Showing signs that the worst may be behind them, the company reported strong growth ahead with a total backlog of anticipated direct revenue of $353.5 million.

To read the full articles for this issue or for more information on these and other breaking stories, please click here!